Open AccessEfficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
Author(s) -
Amit Joshi,
Vijay Patil,
Vanita Noronha,
Anuradha Chougule,
Atanu Bhattacharjee,
Rajiv Kumar,
Supriya Goud,
Sucheta More,
Anant Ramaswamy,
Ashay Karpe,
Nikhil Pande,
Arun Chandrasekharan,
Alok Goel,
Vikas Talreja,
Abhishek Mahajan,
Amit Janu,
Nilendu Purandare,
Kumar Prabhash
Publication year - 2018
Publication title -
lung india
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 25
eISSN - 0974-598X
pISSN - 0970-2113
DOI - 10.4103/lungindia.lungindia_201_17
Subject(s) - gefitinib , exon , epidermal growth factor receptor , medicine , mutation , cancer research , lung cancer , epidermal growth factor , receptor , oncology , genetics , gene , biology
This study was designed to evaluate the differential effect of epidermal growth factor receptor (EGFR) mutation status (exon 19 vs. 21) on progression-free survival (PFS) and overall survival (OS) in treatment-naïve advanced EGFR mutation-positive nonsmall cell lung cancer (NSCLC) treated with gefitinib as first-line agent.